.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Chinese Patent Office
Colorcon
Daiichi Sankyo
Federal Trade Commission
Healthtrust
QuintilesIMS
Argus Health
Dow

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,344,949

« Back to Dashboard

Summary for Patent: 4,344,949

Title: Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
Abstract:Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids and the pharmaceutically acceptable salts thereof are produced by coupling a suitably substituted 1,2,3,4-tetrahydroisoquinoline with a suitably substituted amino acid and when desired hydrolyzing or removing protecting groups of the resulting product. The compounds of the invention, their salts and pharmaceutical compositions thereof are useful as antihypertensive agents.
Inventor(s): Hoefle; Milton L. (Ann Arbor, MI), Klutchko; Sylvester (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:06/236,397
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

International Patent Family for Patent: 4,344,949

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark436081► Subscribe
Germany19575041► Subscribe
Germany3176029► Subscribe
German Democratic Republic201787► Subscribe
Denmark163120► Subscribe
European Patent Office0096157► SubscribeSPC/GB95/011United Kingdom► Subscribe
European Patent Office0049605► SubscribeSPC/GB93/099United Kingdom► Subscribe
Finland79839► Subscribe
Finland881985► Subscribe
Finland813033► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Farmers Insurance
Fuji
Harvard Business School
Queensland Health
Deloitte
Accenture
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot